{"id":"NCT01900899","sponsor":"Pfizer","briefTitle":"Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children","officialTitle":"A PHASE III, OPEN, MULTI-CENTRE, CONTROLLED STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 2, 3, 4, 5 AND 6 YEARS AFTER A BOOSTER DOSE OF MENINGOCOCCAL SEROGROUP A, C, W-135, Y- TETANUS TOXOID CONJUGATE VACCINE (MENACWY-TT) OR MENINGITEC (REGISTERED) ADMINISTERED IN HEALTHY 5-YEAR-OLD CHILDREN IN STUDY MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (112036), WHO WERE PRIMED WITH THE SAME VACCINE IN STUDY MENACWY-TT-039 (109670) AT 12 THROUGH 23 MONTHS OF AGE.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2017-11","completion":"2017-11","firstPosted":"2013-07-17","resultsPosted":"2019-06-17","lastUpdate":"2019-06-17"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"PROCEDURE","name":"Blood Sampling","otherNames":[]}],"arms":[{"label":"ACWY-TT group","type":"EXPERIMENTAL"},{"label":"MenCCRM group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the long-term antibody persistence as well as safety of GSK Biologicals' MenACWY-TT vaccine versus Meningitec up to 6 years after booster vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039 (NCT00474266) at 12 through 23 months of age.","primaryOutcome":{"measure":"Percentage of Participants With rSBA-Antibody Titers Greater Than or Equal to (>=) 1:8 For Each of the 4 Serogroups at 24 Months After Booster Vaccination","timeFrame":"24 months after booster Vaccination","effectByArm":[{"arm":"MenACWY-TT Vaccine","deltaMin":98.4,"sd":null},{"arm":"MenCCRM Vaccine","deltaMin":23.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":10,"countries":["Finland"]},"refs":{"pmids":["32284274"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=MENACWY-TT-102&StudyName=A+Phase+Iii%2C+Open%2C+Multi-centre%2C+Controlled+Study+To+Evaluate+The+Long-term+Antibody+Persistence+At+2%2C+3%2C+4%2C+5+And+6+Years+After+A+Booster+Dose+Of+Meningococcal+Serogroup+A%2C+C%2C+W-135%2C+Y-+Tetanus+Toxoid+Conjugate+Vaccine+%28menacwy-tt%29+Or+Meningitec+%28registried%29+Administered+In+Healthy+5-year-old+Children+In+Study+Menacwy-tt-048+Ext%3A+039+Y2%2C+3%2C+4%2C+5+%28112036%29%2C+Who+Were+Primed+With+The+Same+Vaccine+In+Study+Menacwy-tt-039+%28109670%29+At+12+Through+23+Months+Of+Age."]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":159},"commonTop":["Juvenile idiopathic arthritis"]}}